WANBANGDE PHARMACEUTICAL HOLDING GROUP CO., LTD.

Wanbangde Pharmaceutical Holding Group Co., Ltd.

002082

CNE000001P94

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
4.89 ^CNY	-1.01%		-2.98%	-23.59%

05-20	Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Dividend for the Year 2023	CI
05-08	US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A	MT

Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021.

January 03, 2022 at 11:00 am

From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 4,139,200 shares, representing 0.67% for CNY 50.95 million under the buyback announced on March 15, 2021.

Latest news about Wanbangde Pharmaceutical Holding Group Co., Ltd.

Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Dividend for the Year 2023	05-20	CI
US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A	05-08	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Proposes Final Cash Dividend for the Year 2023	04-26	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Wanbangde Pharma Elects Vice Chairman, Appoints CFO	01-29	MT
Wanbangde Pharma's Anesthesia Passes Drug Regulator's Consistency Evaluation	01-19	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.(XSEC:002082) added to S&P Global BMI Index	23-09-18	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Board Appointments	23-07-31	CI
Wanbangde Pharmaceutical Registers New Medical Device	23-07-10	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 05 June 2023	23-05-30	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Cash Dividend for the Year 2022	23-05-17	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Profit Distribution Proposal for 2022	23-04-26	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.(XSEC:002082) dropped from S&P Global BMI Index	22-12-19	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Wanbangde Pharma in Talks to Buy Controlling Stake in Consun Pharma	22-07-26	MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-13	CI
Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021.	22-03-14	CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback announced on March 15, 2021, has expired with 5,000,000 shares, representing 0.81% for CNY 59.98 million.	22-03-12	CI

Chart Wanbangde Pharmaceutical Holding Group Co., Ltd.

Duration

Period

Chart Wanbangde Pharmaceutical Holding Group Co., Ltd.

More charts

Company Profile

Wepon Pharmaceutical Holding Group Co Ltd, formerly Wanbangde Pharmaceutical Holding Group Co Ltd, is a China-based company mainly engaged in the manufacture of pharmaceuticals and medical devices. The Company primarily operates through three segments. The Pharmaceutical Manufacturing segment is mainly engaged in the research and development, production and sales of modern Chinese medicines, chemical raw materials and chemical preparations. The Medical Device segment is mainly engaged in the research and development of medical devices, medical equipment services and provision of hospital engineering services. The Company also conducts its business through the Other segment. The Company conducts its business in the domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
WANBANGDE PHARMACEUTICAL HOLDING GROUP CO., LTD.	-23.59%	417M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.31%	42.32B
OTSUKA HOLDINGS CO., LTD.	+15.75%	21.29B
SANDOZ GROUP AG	+19.33%	15.29B
CIPLA LIMITED	+18.71%	14.36B
ZYDUS LIFESCIENCES LIMITED	+52.78%	12.81B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.58%	6.58B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.51B